GSK’s Nucala, an IL-5 inhibitor, has demonstrated positive results in the MATINEE Phase 3 trial for treating Chronic Obstructive Pulmonary Disease (COPD). The drug significantly reduced the rate of moderate/severe exacerbations in patients with type 2 inflammation, offering hope for a new treatment option for this widespread respiratory disease.